MedTrace Logo

China Post-Market Clinical Follow-up of FACILLE®

NCT05294562 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1552

Last updated 2022-03-24

No results posted yet for this study

Summary

The results showed that subjects tolerated the Sodium Hyaluronate Gel for Injection (FACILLE®) well, with no systemic AEs, SAEs, and unanticipated AEs and associated with high satisfaction and self-evaluated effectiveness. Nearly half of the subjects maintained correction for 12 months and were satisfied with the product 3 years after the first injection.

Conditions

  • Dermal Filler
  • Hyaluronic Acid
  • Nasolabial Fold

Sponsors & Collaborators

  • SciVision Biotech Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-12-14
Primary Completion
2017-05-07
Completion
2020-05-12

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05294562 on ClinicalTrials.gov